Top Pharma news of the day

Glenmark Pharmaceuticals has now introduced its new third generation oral anti diabetic agent Teneligliptin for type-2 diabetes in India at an affordable price of Rs. 19.90 per tablet. The molecule gliptin comes under the category of DPP-4 inhibitors, which is backed by scientific data as being safe, well tolerated, weight neutral with low risk of hypoglycemia.

AstraZeneca, a global, innovation-driven biopharmaceutical business, announced that the phase III SUMIT study of selumetinib in combination with dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint of progression free survival. This combination therapy showed an adverse event profile generally consistent with current knowledge of the safety profiles of dacarbazine and selumetinib. A full evaluation of the data is ongoing.

Glenmark Pharmaceuticals has now introduced its new third generation oral anti diabetic agent Teneligliptin for type-2 diabetes  in India at an affordable price of Rs. 19.90 per tablet. The molecule gliptin comes under the category of DPP-4 inhibitors, which is backed by scientific data as being safe, well tolerated, weight neutral with low risk of hypoglycemia.

Sanofi posted  nearly 12% growth in net profit at Rs 64.20 crore for the quarter ended June 30, 2015 compared to Rs 57.50 crore for the same quarter last fiscal. 

Animal healthcare player Hester Biosciences Ltd on Wednesday reported net profit of Rs. 4.66 crore for the first quarter ended June 2015, up 7 per cent from Rs. 4.34 crore in the same period last year.